Prevalence of drug-resistant <i>Pseudomonas aeruginosa</i> in Iranian burned patients: A meta-analysis by Tarashi, Samira. et al.
© 2017 Archives of Trauma Research | Published by Wolters Kluwer - Medknow 1
Review Article
intROductiOn
Burn infections are one of the most prevalent and destructive 
health problems in many countries of the world, particularly in 
developing countries like Iran, where in some cases infection 
control programs are ignored. Patients with serious burn 
injury require immediate care to minimize complications. 
One of the most remarkable and serious complications 
of burn is wound infections.[1] It is estimated that about 
75% of the mortality in burn injuries contributes to the 
infection.[2] According to the Centers for Disease Control 
and Prevention (CDC) report in 2013, Enterobacteriaceae, 
Pseudomonas aeruginosa, and Acinetobacter spp. have the 
appearance as significant pathogens caused infection in the 
burn unit. The CDC’s National Healthcare Safety Network 
estimates that approximately 8% of all healthcare-associated 
infections reported are caused by P. aeruginosa.[3] Antibiotic 
therapy is considered as the major intervention in the treatment 
and management of burn infections. Carbapenems including 
imipenem and meropenem are the most important antibiotics 
used to treat P. aeruginosa infections. Imipenem is one of 
the most potent agents against P. aeruginosa. Imipenem 
resistance is a major obstacle to treatment of P. aeruginosa 
infections. Increasing antibiotic resistance is a serious problem 
for both patients and health-care systems.[4,5] Recently, 
this concern has been further intensified by the emergence 
of multidrug-resistant (MDR) strains with the mortality 
rate >40%–50%.[4,6] Thereby, in the past decade, major attempt 
has been done to establish new strategies to progress treatment 
of burned patients. Although numerous studies have been 
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published in burn wound infections and antibiotic resistance 
in Iran, none of them has studied all of the countries within 
a comprehensive study. Having comprehensive and reliable 
data on antibiotic susceptibility status of P. aeruginosa is 
crucial for effective treatment and successful infection control 
program against this bacterium, especially in regions where an 
antibiotic therapy is empirical, and infection control strategy 
is ignored. The aim of the present study was to determine the 
true prevalence of imipenem-resistant P. aeruginosa in Iranian 
burned patients according to the Preferred Reporting Items 
for Meta-Analyses statement. Moreover, resistance to several 
potent anti-P. aeruginosa drugs were indicated according to the 
Clinical and Laboratory Standards Institute (CLSI) guidelines 
for the disc diffusion method.
MAteRiAls And MethOds
Search strategies
A database was constructed to evaluate the prevalence of 
drug-resistant P. aeruginosa in Iranian burned patients from 
March 2006 to May 2015 using PubMed, Web of Science, 
Iranmedex, Scopus, and the Scientific Information Database. 
The search was confined to original articles published in 
English and Persian that present the prevalence or incidence 
of P. aeruginosa in Iranian burned patients. The following 
keywords from Medical Subject Headings or titles or abstracts 
were used with the help of Boolean operators (and, or): 
P. aeruginosa, burned patients, Iran drug susceptibility, and 
drug resistance. The authors searched both English published 
articles and relevant Persian articles. All published data in the 
Persian language including Magiran, Iranian National Library, 
Scientific Information Database, and Iranmedex were searched.
Inclusion and exclusion criteria
All research articles presenting the prevalence of drug-resistant 
P. aeruginosa in burned patients in Iran were selected. Based 
on titles, abstracts, and full papers, the collection of articles 
for review was performed. Method of antibiotic susceptibility 
in all of included studies was based on CLSI guidelines for 
P. aeruginosa against anti-P. aeruginosa drugs including 
imipenem, meropenem, ceftazidime, ceftriaxone, cefepime, 
ciprofloxacin, amikacin, gentamicin, and aztreonam. Studies 
were excluded from analysis for any of the following reasons: 
articles noted only on non-P. aeruginosa; studies done on 
regions except Iran; studies checking the nonburned patient; 
studies that were not performed based on the CLSI guidelines 
and do not use the anti-P. aeruginosa drugs. Review articles, 
congress abstracts, meta-analyses, or systematic reviews, 
studies reported in languages other than English or Persian, 
articles available only in abstract form and also duplicate 
publication of the same study were excluded.
Data extraction
For all studies, the data including year of publication, first 
author, study setting, number of burned patients, and drug 
resistance status were extracted by two persons, independently. 
The term drug resistance among P. aeruginosa refers to 
isolates that according to the CLSI guidelines show resistance 
to suitable antimicrobial tests and grow in the presence of 
antimicrobial agents that would normally kill them or limit 
their growth.
Statistical analysis
Comprehensive Meta-Analysis Software Version 2.0 
(Biostat, Englewood, NJ) was used for statistical analysis. 
The prevalence of drug-resistant P. aeruginosa in burned 
patients in Iran was reported by 95% confidence intervals (CIs). 
Egger weighted regression and Begg’s rank correlation 
methods were used to assess possible publication bias. The 
value of P < 0.05 was considered indicative of a statistically 
significant publication bias. Random effects models were 
chosen according to the Cochrane Q test and I2 tests, taking 
into account the possibility of heterogeneity between studies.
Results
A total of 1071 research articles were selected [Figure 1]. 
Based on title and abstract evaluation, 652 of them were 
excluded, and 419 for full-paper evaluation were retained. 
After this screening, 34 articles describing the prevalence 
of drug-resistant P. aeruginosa in burned patients in Iran are 
selected for analysis and presented in Table 1. Of the included 
articles, 11 articles were considered the age and 13 articles 
reported the gender of the patients. Based on these articles, 
1021 males and 617 females with a mean age between 20 and 
40 years [Table 1] were analyzed. All 34 articles contained 
information for drug-resistant P. aeruginosa in burned patient 
in Iran. All studies had been used the disc agar diffusion 
method according to the CLSI protocols. Considering the 
PubMed, Web of Science, 
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Figure 1: Diagram of the study selection process
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location of the studies, most of the studies were conducted 
in Tehran (n = 15) and compared with studies in Shiraz and 
Ahvaz (each of them n = 3), Sanandaj (each n = 2), Sari, 
Hamadan, Qom, Ilam, Kerman, Urmia, Mashhad, Tabriz, 
Guilan, and Yazd (each n = 1). Figure 2 shows the distribution 
of imipenem-resistant P. aeruginosa in different regions of 
Iran. The prevalence of imipenem resistance was found to be 
54.9% (95% CI, 46.9–62.7). However, evident heterogeneity 
was observed (P < 0.226). Figure 3 shows the forest plot of 
the meta-analysis on imipenem-resistant P. aeruginosa. As 
shown in Figure 4, some evidence for the publication bias 
was observed (P = 0.241 for Begg’s rank correlation analysis; 
P = 0.472 for Egger weighted regression analysis). Common 
data of each selected studies such as first author, published 
time, province, number of P. aeruginosa, and number of 
imipenem resistance were shown in Table 1. Resistance to 
anti-P. aeruginosa drugs that have been selected according to 
the CLSI guidelines for the disc diffusion method was shown in 
Table 1. Considering resistance to anti-P. aeruginosa drugs, the 
most common resistance was seen against ceftazidime (66.9%), 
followed by ciprofloxacin (52.9%), and cefepime (52.3%).
discussiOn
P. aeruginosa is one of the most important nosocomial agents 
and clinical isolates of this opportunistic pathogen cause serious 
infections in burn units.[39] The current meta-analysis showed 
the prevalence and distribution of drug-resistant P. aeruginosa 
in burned patients in Iran. Our analyses showed that 54.9% of 
the P. aeruginosa strains from burned patients were resistant 
to imipenem. Considering that the carbapenems are still 
the drug of choice for MDR P. aeruginosa, this high rate of 
resistance is very alarming.[40] Poorabbas et al. performed a 
study in Iran on antibiotic resistance and reported resistance 
to imipenem (85%), ciprofloxacin (76%), amikacin (70%), 
Table 1: Status of drug‑resistant Pseudomonas aeruginosa isolates
First author Province Published time Case number IMP MEM CAZ CPM CIP AMK GM AZT
Japoni[7] Shiraz 2006 70 47 48 11 2 19 5 - -
Kohanteb[8] Shiraz 2007 30 14 11 30 - 25 28 30 -
Mahini[9] Ahvaz 2007 100 41 23 81 100 - - - -
Owlia[10] Tehran 2007 110 42 - 101 - 85 52 98 -
Khorasani[11] Sari 2008 71 15 58 68 70 35 57 49 -
Mahouf[12] Hamadan 2008 57 30 27 35 45 24 22 36 14
Saderi[13] Tehran 2008 128 49 - 95 - 63 83 107 -
Mirsalhian[14] Tehran 2008 100 63 66 85 88 83 - - 90
Khosravi[15] Ahvaz 2008 100 41 41 83 100 - - - -
Afrasiabian[16] Sanandaj 2008 16 1 - 13 - 5 1 6 -
Bahar[4] Sanandaj 2010 115 115 - 115 - 89 94 115 -
Zolfaghari[17] Qom 2011 40 20 - 21 - 19 10 12 -
Mirsalehian[18] Tehran 2010 170 112 118 141 144 142 - - 150
Alipour[19] Ilam 2010 53 2 - 21 - - 35 - 14
Alipour[19] Kerman 2010 120 0 - 78 - - 69 - 72
Saderi[20] Tehran 2010 100 69 - 78 - 55 73 86 -
Jazani[21] Urmia 2010 100 47 - 100 75 70 70 97 -
Jabalameli[22] Tehran 2011 112 74 79 94 98 95 92 - 101
Bayat[23] Urmia 2011 20 20 - 20 20 20 20 20 -
Ranjbar[24] Tehran 2011 70 68 - 40 - 45 63 47 -
Rezaei[25] Mashhad 2011 28 5 5 27 11 17 16 - -
Vahdani[26] Tehran 2012 220 174 - 178 191 191 174 158 178
Sepehriseresht[27] Tabriz 2012 483 272 - - - - - - -
Nikokar[28] Guilan 2013 86 20 59 - 57 42 32 -
Jafari[29] Tehran 2013 100 77 100 77 100 100 100 49 100
Fallah[30] Tehran 2013 100 83 48 48 48 48 48 49 48
Moazami-Goudarzi[31] Tehran 2013 133 126 126 119 122 127 119 - 125
Vala[32] Tehran 2013 47 37 35 31 32 33 - 34 33
Goudarzi[33] Tehran 2014 73 47 72 - 73 71 72 -
Akhavan-Tafti[34] Yazd 2014 54 40 38 - 34 - - 40 -
Farshadzadeh[35] Ahvaz 2014 185 55 111 149 157 55 - - 182
Neyestanaki[36] Tehran 2014 214 100 100 180 213 100 - 100 100
Japoni[37] Shiraz 2014 270 60 60 207 265 265 252 265 60
Hakemi Vala[38] Tehran 2014 47 37 35 34 32 32 - 34 39
Mean rate (%) - - 54.9 30.3 66. 9 52.3 52.9 42.8 41.2 35
IMP: Imipenem, MEM: Meropenem, CAZ: Ceftrixone, CPM: Cefepime, CIP: Ciprofloxacin, AMK: Amikacin, GM: Gentamycin, AZT: Aztreonam
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Figure 2: Distribution of imipenem‑resistant Pseudomonas aeruginosa in different regions of Iran
gentamicin (67%), cefepime (40%), and ceftazidime (74%) 
in burn patients.[41] Other study from India, in 2015, indicated 
resistance to gentamicin (84%), ceftazidime (76.79%), 
amikacin (73.2%), ciprofloxacin (71.4%), and imipenem (61%) 
in burn patients.[42] The development of imipenem resistance 
among P. aeruginosa strains in burn units may contribute to 
the factors such as the severity of burn infection which result 
in long hospitalization time in particular intensive care unit 
stay, previous broad-spectra antibiotics use or monotherapy 
that increase risk of resistance, poor laboratory diagnosis 
of resistance isolates that can cause to increase transferring 
resistance to other susceptible germs and higher costs that 
may lead to prescribe inappropriate and cheaper drug or use 
of monotherapy.[43,44] Carbapenem-resistance mechanisms in 
P. aeruginosa isolates are in association with resistance to 
other antibiotic classes such as penicillins, cephalosporins, and 
monobactams probably due to similar resistance mechanisms 
and make treatment very challenging.[45,46] Hence, identifying 
and detection of carbapenem-resistant strains and using the 
infection control procedures are very important.[47] In addition, 
resistance can be transferred to P. aeruginosa by mobile elements 
such as plasmids or integrons. In low hygiene condition on 
burn units, colonization of other microorganisms such as 
Enterobacteriaceae and A. baumannii may lead to transfer the 
resistance coding elements to the P. aeruginosa.[48,49] According 
to the geographic areas, classified analyses were done in the 
current study. Most of the studies were performed in Tehran, 
where high rates of imipenem resistance (65.8%) compared 
to other regions have been reported by researchers. These 
findings may supported that Tehran, the capital of Iran, with 
many health-care centers play a referral role for other regions of 
Iran and burned patients with drug-resistant P. aeruginosa are 
mostly referred to this province. The Central and Northwest of 
Iran showed almost high imipenem resistance (50%), whereas 
the South and West of Iran were moderate (almost 30%) and 
the East of Iran was experienced the lowest rate of imipenem 
resistance (<20%). Based on this finding, distribution of 
imipenem resistance in Iran is not homogeneous that reported 
in range of 0% (Southeast of Iran) to 88.5% (West of Iran). 
This pattern is similar to India where based on different studies 
the imipenem-resistance rate varies from 10% to 95.7%. 
According to data released from CDC, several ways exist 
to prevent drug-resistant P. aeruginosa infections including 
knowledge about resistance trends in a specific region, and 
coordinating the local and regional infection control efforts; 
the results should be made available more rapidly to clinicians 
for suitable treatment.[50] Moreover, hospitalization time should 
be shortened if possible; effective and appropriate antibiotic 
policies should be implemented; staff should be educated about 
the significance of right antibiotic use; and some strategies 
are necessary to optimize the use of antibiotics, for example, 
the prescription of carbapenem.[43,51] Finally, essentials of the 
standard precautions should be taken.[52] Every assay should be 
done to reduce spreading and emerging of resistant organisms.[53] 
We suggest that the infection control program recommended 
by the World Health Organization be implemented according 
to local conditions to be more effective. In the other words, 
countries with low- and middle-income are not able to apply 
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infection control programs as developed countries in terms 
of cost and cultural requirements.[54,55] Close cooperation of 
clinicians with the microbiology laboratory, rapid reporting, and 
effective treatment using combination regimens is necessary 
to prevent spread of resistant P. aeruginosa isolates in burned 
patients.[54,56,57] However, combination regimens should be used 
very carefully only in inpatient who has indication, otherwise 
may lead to new resistance.[58] The limitations of this review 
should be discussed as follows: (a) it cannot fully represent the 
prevalence of imipenem resistance in P. aeruginosa in Iran due 
to the imipenem resistance is not yet investigated in many areas 
of Iran. (b) The potential influence of age and sex could not 
be analyzed because of the limited information obtained from 
the studied articles. (c) Only the disc diffusion test was used 
in selected studies and other confirmatory tests such as E-test 
or minimal inhibitory concentration were not used. (d) The 
heterogeneity exists among the included studies. (e) As with any 
meta-analysis, limitations associated with potential publication 
bias should be considered.
cOnclusiOn
This meta-analysis showed that P. aeruginosa resistance was 
high among isolates with burn infection, which may lead to 
more cost and high rate of mortality. Thereby, attention to 
infection control guidelines, creating close relation between 
physicians and laboratory, and continuous monitoring of drug 
resistance are highly recommended. It is necessary to know 
the epidemiology of drug-resistant P. aeruginosa because it 
can promote control strategies for decreasing their prevalence. 
The high incidence of drug-resistant P. aeruginosa in Iran 
emphasizes the need for precise drug susceptibility testing, 
continuous monitoring of drug resistance, especially in burn 
units, use of sensitive methods for the laboratory diagnosis, 
and close relation between physician and laboratories.
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